This site is intended for health professionals only

Single-dose Covid vaccine proves effective; while Oxford jab approved by EU

Single-dose Covid vaccine proves effective; while Oxford jab approved by EU

A single-dose regime of the Covid vaccine candidate developed by Janssen has proved 66% effective in phase 3 trials.

The UK has already pre-ordered 30 million doses of the vaccine, which can now be reviewed by the MHRA for regulatory approval.

Commenting on the Janssen trials, which included 6,000 UK-based participants, the UK Government said a single-dose vaccine ‘would offer a significant advantage during a global pandemic emergency’.

However, further trials are ongoing to see if a two-dose regimen offers greater protection or durability.

Meanwhile, the Oxford/AstraZeneca Covid vaccine, which is already part of the UK’s vaccination campaign, has now also been approved by the European medicines regulator, according to a BBC breaking news report this afternoon.

The EU has bought 400 million doses of the AstraZeneca vaccine, however the parties have recently been in a disagreement about supply in the early stages of the vaccination rollout.

Meanwhile, German authorities have advised that the Oxford jab should not be used in over-65s amid a lack of data on efficacy. However, AstraZeneca and the UK Government have both rebutted claims.


Visit Pulse Reference for details on 140 symptoms, including easily searchable symptoms and categories, offering you a free platform to check symptoms and receive potential diagnoses during consultations.